TrivarX Ltd
TRI
Company Profile
Business description
TrivarX Ltd is a health technology company developing AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions. Trivarx’s clinical research has enabled the development of cutting-edge proprietary algorithms for spectral analyses of sleep architecture and heart rate variability. The Company has one operating segment, being the research, development and commercialisation of its software asaService product, and two geographical locations, being Australia and the United States.
Contact
647 Beaufort Street
Mount LawleyWA6050
AUST: +61 861891155
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2026
Employees
4
Stocks News & Analysis
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,194.90 | 12.40 | -0.13% |
| CAC 40 | 8,146.75 | 112.19 | -1.36% |
| DAX 40 | 25,038.25 | 258.88 | -1.02% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,199.24 | 36.05 | -0.35% |
| HKSE | 26,563.90 | 281.06 | -1.05% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,583.57 | 352.60 | -0.65% |
| NZX 50 Index | 13,580.29 | 137.81 | -1.00% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,874.50 | 9.20 | -0.10% |
| SSE Composite Index | 4,114.00 | 12.09 | 0.29% |